Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Neurocrine Biosciences Posts Sizzling Sales Growth in Q2

By Keith Speights - Jul 30, 2019 at 6:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Sales soared for the drug Ingrezza. And key pipeline developments are on the way.

Neurocrine Biosciences ( NBIX 1.18% ) shareholders should be pleased with the stock so far in 2019. The biotech's share price is up more than 30% year to date. And it reported solid revenue growth in its first-quarter results announced in April. 

Anyone wondering if Neurocrine could keep the momentum going got a strong affirmative when the company announced its second-quarter results after the market closed on Monday. It again delivered a solid performance. 

Folded dollar bill shaped into an arrow pointing up

Image source: Getty Images.

By the numbers

Top-line performance improved significantly in the second quarter. Revenue jumped nearly 90% year over year to $183.6 million. Analysts estimated that the company's revenue for the Q2 would come in at $163.14 million.

The biopharmaceutical company reported net income under generally accepted accounting principles (GAAP) of $51.3 million, or $0.54 per share. This was a major improvement over the prior-year period when the company announced a net loss of $5.9 million, or $0.07 per share. Analysts were expecting Q2 adjusted earnings of $0.11 per share.

Neurocrine ended the second quarter with cash, cash equivalents, and short-term investments of $766.5 million as of June 30, 2019.

Behind the numbers

Most of the revenue in Q2 was generated by the tardive dyskinesia drug Ingrezza. Sales for Ingrezza jumped 86% year over year to $180.5 million. The company also reported collaboration revenue of a little over $3 million. 

This sales growth for Ingrezza also drove the company's net income higher. And it benefited from a $21 million gain from its equity investment in Voyager Therapeutics

But spending increased significantly in the second quarter. Research and development (R&D) jumped 67% year over year to $61.7 million. Part of this increase was related to the acceptance by the Food and Drug Administration of the New Drug Application for opicapone. Sales, general, and administrative (SG&A) expenses also increased 33% year over year to $80.8 million, driven primarily by the expansion of Neurocrine's sales force and other promotional efforts.

Looking ahead

Neurocrine projects that its operating expenses for full-year 2019 will be between $658 million and $688 million. Ongoing expenses for SG&A and R&D are now anticipated to be between $540 million and $570 million, lower than the company's previous guidance range of $550 million to $600 million.

The company has several pipeline developments to watch in the not-too-distant future. Its partner AbbVie should file for FDA approval of elagolix in treating uterine fibroids later this year. The FDA is scheduled to make an approval decision on opicapone as an adjunctive therapy to levodopa/carbidopa in patients with Parkinson's disease by April 26, 2020. Neurocrine also plans to talk with the FDA in the third quarter of this year about advancing its NBI-74788 program in adult patients with congenital adrenal hyperplasia. 

All of this activity has CEO Kevin Gorman pretty fired up. "We are pleased with this exciting progress and remain on track to have three FDA-approved treatments in four indications by 2020," Gorman said. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Neurocrine Biosciences, Inc. Stock Quote
Neurocrine Biosciences, Inc.
NBIX
$84.23 (1.18%) $0.98
AbbVie Inc. Stock Quote
AbbVie Inc.
ABBV
$118.95 (3.19%) $3.67
Voyager Therapeutics Stock Quote
Voyager Therapeutics
VYGR
$3.12 (2.47%) $0.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
656%
 
S&P 500 Returns
144%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/01/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.